Pharmacokinetics of tacrolimus during pregnancy

Therapeutic Drug Monitoring

Volumn 34, Issue 6, 2012, Pages 660-670

  Zheng, Songmao ^a   Easterling, Thomas R ^b,c   Umans, Jason G ^d,e,f,g   Miodovnik, Menachem ^e,f   Calamia, Justina C ^a   Thummel, Kenneth E ^a   Shen, Danny D ^a,c   Davis, Connie L ^c   Hebert, Mary F ^b,c  

^a Departments of Pharmaceutics   (United States)

^b Obstetrics and Gynaecology   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d MEDSTAR RESEARCH INSTITUTE   (United States)

^e WASHINGTON HOSPITAL CENTER   (United States)

^f GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^g Delaware   (United States)

Author keywords

hematocrit; pregnancy; serum albumin; tacrolimus dose adjustment; tacrolimus unbound concentration

Indexed keywords

ALBUMIN; TACROLIMUS;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DRUG BLOOD LEVEL; DRUG METABOLISM; ERYTHROCYTE COUNT; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HEMATOCRIT; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; STEADY STATE; THIRD TRIMESTER PREGNANCY; URINALYSIS;

ADULT; BIOTRANSFORMATION; CARBON ISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METABOLIC CLEARANCE RATE; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, THIRD; SERUM ALBUMIN; TACROLIMUS; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84870061265     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182708edf     Document Type: Article

References (62)

1. Scott LJ, McKeage K, Keam SJ, et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs. 2003;63:1247-1297. (Pubitemid 36750952)
2. McKay DB, Josephson MA. Pregnancy in recipients of solid organs -effects on mother and child. N Engl J Med. 2006;354:1281-1293.
3. Coscia LA, Constantinescu S, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl. 2010:65-85.
4. Jusko WJ, Thomson AW, Fung J, et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit. 1995;17: 606-614.
5. Machida M, Takahara S, Ishibashi M, et al. Effect of temperature and hematocrit on plasma concentration of FK 506. Transplant Proc. 1991; 23:2753-2754.
6. Akbas SH, Ozdem S, Caglar S, et al. Effects of some hematological parameters on whole blood tacrolimus concentration measured by two immunoassay-based analytical methods. Clin Biochem. 2005;38:552-557. (Pubitemid 40693470)
7. Undre NA, Stevenson P, Schafer A. Pharmacokinetics of tacrolimus: clinically relevant aspects. Transplant Proc. 1999;31:21S-24S.
8. Undre NA, van Hooff J, Christiaans M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc. 1999;31: 296-298.
9. Undre NA. Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant. 2003;18(suppl 1):i12-i15. (Pubitemid 36722543)
10. Sattler M, Guengerich FP, Yun CH, et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992;20:753-761.
11. Lampen A, Christians U, Guengerich FP, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos. 1995; 23:1315-1324.
12. Lin YS, Dowling AL, Quigley SD, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol. 2002;62:162-172.
13. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383-391.
14. Haehner BD, Gorski JC, Vandenbranden M, et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol. 1996; 50:52-59.
15. Givens RC, Lin YS, Dowling AL, et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol. 2003;95:1297-1300.
16. Dai Y, Hebert MF, Isoherranen N, et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos. 2006;34:836-847.
17. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part II. Clin Pharmacokinet. 2010;49: 207-221.
18. Tuteja S, Alloway RR, Johnson JA, et al. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation. 2001;71:1303-1307.
19. Floren LC, Bekersky I, Benet LZ, et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther. 1997;62:41-49.
20. Hebert MF, Fisher RM, Marsh CL, et al. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol. 1999;39: 91-96.
21. Fuchs KM, Coustan DR. Immunosuppressant therapy in pregnant organ transplant recipients. Semin Perinatol. 2007;31:363-371.
22. Hebert MF, Easterling TR, Kirby B, et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin Pharmacol Ther. 2008;84:248-253.
23. Tracy TS, Venkataramanan R, Glover DD, et al. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol. 2005;192:633-639.
24. Hirt D, Treluyer JM, Jullien V, et al. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women. Antimicrob Agents Chemother. 2006;50:2079-2086.
25. Villani P, Floridia M, Pirillo MF, et al. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. Br J Clin Pharmacol. 2006;62:309-315.
26. Yokogawa K, Takahashi M, Tamai I, et al. P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice. Pharm Res. 1999;16:1213-1218.
27. Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268:6077-6080.
28. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood. 1992;80:2735-2739.
29. Feghali MN, Mattison DR. Clinical therapeutics in pregnancy. J Biomed Biotechnol. 2011;2011:783528.
30. Piekoszewski W, Jusko WJ. Plasma protein binding of tacrolimus in humans. J Pharm Sci. 1993;82:340-341.
31. Weiss HM, Fresneau M, Moenius T, et al. Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application. Drug Metab Dispos. 2008;36: 1812-1818.
32. Hytten F. Blood volume changes in normal pregnancy. Clin Haematol. 1985;14:601-612.
33. Zahir H, McCaughan G, Gleeson M, et al. Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol. 2004;57:298-309.
34. Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther. 1995;57: 281-290.
35. Piekoszewski W, Chow FS, Jusko WJ. Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance. Drug Metab Dispos. 1993;21:690-698.
36. Chow FS, Piekoszewski W, Jusko WJ. Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion. Drug Metab Dispos. 1997;25:610-616. (Pubitemid 27213103)
37. Midtvedt K, Hartmann A, Brekke IB, et al. Successful pregnancies in a combined pancreas and renal allograft recipient and in a renal graft recipient on tacrolimus treatment. Nephrol Dial Transplant. 1997;12: 2764-2765.
38. French AE, Soldin SJ, Soldin OP, et al. Milk transfer and neonatal safety of tacrolimus. Ann Pharmacother. 2003;37:815-818. (Pubitemid 36618367)
39. Fehrman-Ekholm I, Nisell H. A successful pregnancy in a kidney recipient with tacrolimus (Prograf, FK 506) therapy. Nephrol Dial Transplant. 1998;13:2982-2983.
40. Christians U, Radeke HH, Kownatzki R, et al. Isolation of an immunosuppressive metabolite of FK506 generated by human microsome preparations. Clin Biochem. 1991;24:271-275.
41. Chen YL, Hirabayashi H, Akhtar S, et al. Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-Tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2006; 830:330-341.
42. Nakai D, Kumamoto K, Sakikawa C, et al. Evaluation of the protein binding ratio of drugs by a micro-scale ultracentrifugation method. J Pharm Sci. 2004;93:847-854.
43. Minematsu T, Sugiyama E, Kusama M, et al. Effect of hematocrit on pharmacokinetics of tacrolimus in adult living donor liver transplant recipients. Transplant Proc. 2004;36:1506-1511.
44. Thompson EE, Kuttab-Boulos H, Yang L, et al. Sequence diversity and haplotype structure at the human CYP3A cluster. Pharmacogenomics J. 2006;6:105-114.
45. Zahir H, Nand RA, Brown KF, et al. Validation of methods to study the distribution and protein binding of tacrolimus in human blood. J Pharmacol Toxicol Methods. 2001;46:27-35.
46. Garcia-Donaire JA, Acevedo M, Gutierrez MJ, et al. Tacrolimus as basic immunosuppression in pregnancy after renal transplantation. A singlecenter experience. Transplant Proc. 2005;37:3754-3755.
47. Kainz A, Harabacz I, Cowlrick IS, et al. Analysis of 100 pregnancy outcomes in women treated systemically with tacrolimus. Transpl Int. 2000;13(suppl 1):S299-S300.
48. Moller A, Iwasaki K, Kawamura A, et al. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos. 1999;27:633-636. (Pubitemid 29252435)
49. Benet LZ, Zia-Amirhosseini P. Basic principles of pharmacokinetics. Toxicol Pathol. 1995;23:115-123.
50. Wilkinson GR. Clearance approaches in pharmacology. Pharmacol Rev. 1987;39:1-47. (Pubitemid 17048545)
51. Staatz CE, Willis C, Taylor PJ, et al. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther. 2002;72:660-669.
52. Staatz CE, Willis C, Taylor PJ, et al. Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl. 2003;9:130-137.
53. Tada H, Tsuchiya N, Satoh S, et al. Impact of CYP3A5 and MDR1 (ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc. 2005;37:1730-1732.
54. Passey C, Birnbaum AK, Brundage RC, et al. Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol. 2011;72:948-957.
55. Shen DD, Kunze KL, Thummel KE. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev. 1997;27:99-127.
56. Beysens AJ, Wijnen RM, Beuman GH, et al. FK 506: monitoring in plasma or in whole blood? Transplant Proc. 1991;23:2745-2747.
57. Hashimoto Y, Sasa H, Shimomura M, et al. Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. Pharm Res. 1998;15:1609-1613.
58. Kolars JC, Awni WM, Merion RM, et al. First-pass metabolism of cyclosporin by the gut. Lancet. 1991;338:1488-1490.
59. Arima H, Yunomae K, Hirayama F, et al. Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus. J Pharmacol Exp Ther. 2001;297:547-555.
60. Zheng S, Tasnif Y, Hebert MF et al. Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition. Clin Pharmacol Ther. [Epub ahead of print] Oct 17, 2012. doi: 10.1038/clpt.2012.175.
61. Trull A, Hughes V, Cooper D, et al. Influence of albumin supplementation on tacrolimus and cyclosporine therapy early after liver transplantation. Liver Transpl. 2002;8:224-232.
62. Undre NA, Schafer A. Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. Transplant Proc. 1998;30: 1261-1263.